If all goes according to plan, Sumitomo Dainippon Pharma Co. Ltd. (SDP) is planning to have up to 11 compounds nominated for clinical development in both the psychiatry/neurology and oncology areas by the end of next fiscal year.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?